Navigation Links
Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
Date:6/28/2009

e three pivotal phase III studies demonstrated that add-on therapy with once-daily Zebinix(R) (800mg and 1200mg) was effective in reducing partial-onset seizures in patients not controlled with one of the most commonly used anti-epileptics, carbamazepine (CBZ), (p<0.01 and p<0.0001 respectively)(3).

Across the clinical studies conducted, eslicarbazepine acetate has demonstrated a favourable safety profile(5). This has been further reinforced by a pooled analysis indicating that most adverse events begin within the first weeks of treatment but after six weeks, no relevant difference was found between eslicarbazepine acetate and placebo(4).

Zebinix(R), researched and developed by BIAL, received marketing authorisation from the European Commission in April 2009, as adjunctive therapy in adults with partial-onset seizures, with or without secondary generalisation. Under the terms of a deal with BIAL, announced in February this year, Eisai Europe Ltd received a sole license to market, promote and distribute ESL within Europe**. Eisai and BIAL plan to launch Zebinix(R) across Europe during 2009 and into 2010, providing a novel and effective treatment to patients with partial-onset seizures who are not adequately controlled with their existing medications. The rights to commercialise the product in the U.S. and Canadian markets were licensed to Sepracor Inc., in late 2007 (the proposed name for eslicarbazepine acetate in the U.S. and Canada is STEDESA(TM)). In June 2009, Sepracor announced that the U.S. Food and Drug Administration (FDA) accepted for filing its New Drug Application (NDA) for STEDESA(TM) as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy, and the NDA is currently under formal review.

Notes to Editors

* Zebinix(R) is the EU trade name for eslicarbazepine acetate.

** European Territories

Austria, Belgium, Bulga
'/>"/>

SOURCE BIAL
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
2. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
3. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
4. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
5. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
6. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
9. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
10. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
11. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 ... Market by Composition of Material, Application (Healthcare, Homeland ... End Product (Personal Instrument, Hand-Held Instruments, Fixed, and ... Analysis to 2013 - 2020", published by MarketsandMarkets, the Scintillator ... of 5.62% from 2014 to 2020, and reach ...
(Date:7/11/2014)... , July 11, 2014  Australian drug delivery company, ... it has raised A$19.3 million via a placement of ... , the U.S., Asia ... from a share purchase plan (SPP) to be offered ... be made in two tranches. "This capital ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... the addition of the "Immunoprotein Diagnostic Testing ... at the highest CAGR of 6% and is ... report to their offering. ... for immunoprotein diagnostic testing has been segmented according ...
Breaking Medicine Technology:Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
(Date:7/12/2014)... Restore My Vision Today is a ... a couple boasting very impressive credentials on the field ... Today as a way to help consumers do without ... their respective patients’ treatments . , In ... trove of pertinent information relevant to eye care like:, ...
(Date:7/12/2014)... 2014 The largest pure occupational medicine ... to announce that it will be opening its fifth ... will join four Atlanta-based Nova Medical Centers’ locations. The ... Deans Bridge Road, and will be open from 8:30 ... “With Nova’s treatment philosophy of rapid return-to-work and decreased ...
(Date:7/11/2014)... 2014 Recently, DressyQuinceanera.com, a well-known wedding ... Dama dresses to its online category. Furthermore, the ... at deeply discounted rates, up to 62% off. , ... equally excellent in terms of quality and style. All ... discounts are also offered for the company’s other items: ...
(Date:7/11/2014)... 11, 2014 Ticket Down reports that tickets ... and 3rd place World Cup Match between Brazil and ... will take place on Saturday, July 12th at Estadio Nacional ... Finals will take place on Sunday, July 13th at Estadio ... All tickets for the 2014 World Cup are guaranteed to ...
(Date:7/11/2014)... FRIDAY, July 11, 2014 (HealthDay News) -- Reducing the ... incidence of Lyme disease and other tick-borne infections ... that deer populations can be manipulated to reduce human ... of contracting Lyme disease," the researchers wrote. White-tailed ... which transmit Lyme disease to people. The study ...
Breaking Medicine News(10 mins):Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2Health News:DressyQuinceanera.com: Beautiful Quinceanera Dama Dresses At Low Prices 2Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2
... Survivors , Breast cancer survivors, particularly older ... non-cancer causes than from breast cancer. , ... longer, and many are dying of causes unrelated ... with the National Cancer Institute of Canada Clinical ...
... responsive to treatment than those with HPV-negative tumors , , ... cancer patients whose tumors test positive for human papillomavirus ... treatment than those who test negative, a new study ... to be responsible for most cervical cancers, has recently ...
... Commitment to Healthy Eating, Active Living and Safety ... ... the fourth,quarter of 2007, Kaiser Permanente approved 778 community benefit grants,totaling ... improve the health of the communities that it,serves. Funds were pledged ...
... Memorial,HealthCare, corporate parent of Northwestern Memorial Hospital, appointed,at ... to the Northwestern,Memorial Foundation,s Boards of Directors., ... as president of the Friends of Prentice,board of ... Hospital,s,Campaign Steering Committee. Gordon is chairman of Boyden ...
... and 100 mcg/hr) Not Affected, RARITAN, N.J., ... said today that all lots of 25,microgram/hour (mcg/hr) ... in the United States and all 25 mcg/hr ... States are being voluntarily,recalled as a precaution from ...
... Help Pediatric Group Improve Claims Processing, ... Appointment Scheduling and Patient Statements, ... completed an agreement with Huntsville Pediatric Associates,to provide ... helps improve appointment scheduling, medical,billing, electronic claims submission, ...
Cached Medicine News:Health News:Other highlights in the Feb. 12 JNCI 2Health News:Other highlights in the Feb. 12 JNCI 3Health News:Other highlights in the Feb. 12 JNCI 4Health News:Kaiser Permanente Approves $29 Million in Community Benefit Grants 2Health News:Kaiser Permanente Approves $29 Million in Community Benefit Grants 3Health News:Northwestern Memorial HealthCare and Northwestern Memorial Foundation Elect New Members to Board of Directors 2Health News:PriCara(TM) Recalls 25 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches 2Health News:Huntsville Pediatric Associates Selects DST Health Solutions' Practice Management Solution for Billing, Accounts Receivable 2
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
FREEDOM® Memory Thumb Spica lets you make a custom splint in minutes. Immerese in 160 F water until pliable, and remove. Amazingly, it maintains its shape and is ready to be precisely, profession...
Qualcare™ Thumb Spica...
... of the thumb, known as deQuervain's tenosynovitis, ... ThumSaver CMC Long provides wrist and thumb ... is positioned for pinch without straining to ... a sleeve. Also ideal following cast removal ...
Medicine Products: